Index
Congenital heart defects are a major cause of mortality after birth, affecting up to 1% of newborns. The vast majority of cases could be detected during fetal screening ultrasound exams. However, this exam is technically challenging and in practice, 50% of cases are missed, thus limiting palliation options for the babies.
BrightHeart is a start-up co-founded by two pediatric cardiologists, experts in fetal cardiac ultrasounds. We are developing an AI-based platform to provide real-time guidance to fetal medicine healthcare professionals during prenatal ultrasound screening exams and support them with the detection of congenital defects. Our goal is to make expert-level prenatal screening diagnosis accessible to all, and inform decisions for pregnancy, delivery and therapeutic management.
We are funded and incubated by Sofinnova MD Start III, an efficient 3-in-1 "accelerator" structure. Their mission is to incubate medical device innovations to the point where proof-of-principle in patients is demonstrated, allowing for interest from traditional investors and their continued funding. Their team operates the projects and builds new companies to bridge the gap between science and clinical experience. Through this, BrightHeart benefits from a robust network of strategics, advisors, and investors.
We are currently a small team with experience in the field, working with expert partners, and funded. We want to move fast by hiring top level talents!
More info: https://www.brightheart.ai
At BrightHeart, we believe every single fetal ultrasound screening exam should be performed with the highest level of accuracy, so each mother and baby receive the highest possible quality of care.